enzastaurin (LY317615) prevent smokers randomized study of lung cancer two
Before the test, the survey found that this drug in precancerous lesions and early lung cancer to inhibit PKC-β pathway and interference effects. In the intent to treat analysis, 40 randomized participants prior to treatment / treatment Ki-67 LI changes in enzastaurin and placebo groups there was no significant difference (P = 0.53). 6 subjects discontinued use of enzastaurin, including 4 adverse events, including bloating, deep vein thrombosis, hyponatremia, and rash; 2 participants decided to terminate the test. 1 subjects stopped because of poor compliance with placebo. Two subjects had ≥ 1 serious adverse event entries (bradycardia, deep vein thrombosis and hypotension).
enzastaurin (LY317615) prevent smokers randomized study of lung cancer two
ReplyDeleteBefore the test, the survey found that this drug in precancerous lesions and early lung cancer to inhibit PKC-β pathway and interference effects. In the intent to treat analysis, 40 randomized participants prior to treatment / treatment Ki-67 LI changes in enzastaurin and placebo groups there was no significant difference (P = 0.53). 6 subjects discontinued use of enzastaurin, including 4 adverse events, including bloating, deep vein thrombosis, hyponatremia, and rash; 2 participants decided to terminate the test. 1 subjects stopped because of poor compliance with placebo. Two subjects had ≥ 1 serious adverse event entries (bradycardia, deep vein thrombosis and hypotension).
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
E-3810
TG 100572 Hydrochloride
TG 100801
TG 100801 Hydrochloride
BMS-690514
Apatinib
Navitoclax
Obatoclax
HA14-1
TW-37